A practical reference on PPARδ agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Space and Strategic Defense Command SSDD (i) Same Shit, Different Day Single-Sided Double-Density (floppy disk) SSE (s) South-southeast (i) Streaming SIMD Extensions SSG – (s) Guided Missile Submarine (retired US Navy hull classification) SSGN – (s) Nuclear-Powered Guided Missile Submarine (US Navy hull classification) SSH – (i) Saffir-Simpson Hurricane scale SSK – (s) Hunter-Killer Submarine (retired US Navy hull classification) SSKP – (i) Single-Shot Kill Probability SSL – (i) Secure Sockets Layer SSM – (i) Surface-to-Surface (Guided) Missile SSN (s) Nuclear-Powered Attack Submarine (US Navy hull classification) (i) SIM Serial Number Social Security Number (U.S.) Socialist Solidarity Network Subsystem number (SCCP, SS7) SSNW – (i) Same Shit, New Wrapping SSO – (s) Submarine Oiler (retired US Navy hull classification) SSP – (s) Submarine Transport (retired US Navy hull classification) SSR (s) Radar Picket Submarine (retired US Navy hull classification) (i) Solid State Recorder SSRI (i) Selective Serotonin Reuptake Inhibitor Social Systems Research Institute SSRN (i) Social Science Research Network (s) Nuclear-Powered Radar Picket Submarine (retired US Navy hull classification) SSS (i) Siding Spring Survey Side Side Side (an acronym for remembering congruent triangles) (i) Sigue Sigue Sputnik (band) S/SSM – (i) Surface-to-Subsurface Missile SST (i) SuperSonic Transport (s) Training Submarine (US Navy hull classification) Saturated Suction Temperature (refrigeration cycles) SSTO – (i) Single-Stage To Orbit SSV – (i) Soft-Skinned Vehicle (i.e., unarmoured) ssw – (s) Swati language (ISO 639-2 code) SSW – (s) South South-West
Stuart Hall (born 1929), a TV presenter convicted of indecent assault, lived in Wilmslow from 1958 to 2013 William Roache (born 1932) actor, plays Ken Barlow in Coronation Street since 1960; he has lived in Wilmslow for most of his adult life John Waite (born 1951), a presenter on British radio and TV, attended Wilmslow High School Barbara Wilshere (born 1959), an actress appearing in theatre, films and on TV, attended Wilmslow High School Jo Wheeler (born 1963), weather forecaster for Sky News, attended Wilmslow High School Fionnuala Ellwood (born 1964), an actress, portrayed Lynn Whiteley in the ITV soap Emmerdale, attended Wilmslow High School Miranda Sawyer (born 1967), journalist and broadcaster, and her brother Toby (born 1969), actor, grew up locally Chris Hawkins (born 1975), presenter and journalist, and his wife Clare Nasir (born 1970), meteorologist, have lived locally since 2012 Simon Gregson (born 1974), actor who plays taxi boss Steve McDonald in Coronation Street Ashley Taylor Dawson (born 1982), actor and singer, plays Darren Osborne in the Channel 4 soap opera Hollyoaks.
== See also == 2026 deaths in the US 2026 in American music 2026 in American television List of American films of 2026 List of animated feature films of 2026 2026 NFL season 2026–27 NHL season 2026–27 NBA season 2026 Major League Baseball season
== Nuclear energy applications == In a fission nuclear reactor, uranium-238 can be used to generate plutonium-239, which itself can be used in a nuclear weapon or as a nuclear-reactor fuel supply. In a typical nuclear reactor, up to one-third of the generated power comes from the fission of 239Pu, which is not supplied as a fuel to the reactor, but rather, produced from 238U. A certain amount of production of 239Pu from 238U is unavoidable wherever it is exposed to neutron radiation. Depending on burnup and neutron temperature, different shares of the 239Pu are converted to 240Pu, which determines the "grade" of produced plutonium, ranging from weapons grade, through reactor grade, to plutonium so high in 240Pu that it cannot be used in current reactors operating with a thermal neutron spectrum. The latter usually involves used "recycled" MOX fuel which entered the reactor containing significant amounts of plutonium.
Sources: en.wikipedia.org
== Modes of industrial operation == Most industrial fermentation uses batch or fed-batch procedures, although continuous fermentation can be more economical if various challenges, particularly the difficulty of maintaining sterility, can be met.
Shaka was the illegitimate son of Senzangakhona, Chief of the Zulus. He was born c. 1787. He and his mother, Nandi, were exiled by Senzangakhona, and found refuge with the Mthethwa. Shaka fought as a warrior under Dingiswayo, leader of the Mthethwa Paramountcy. When Senzangakona died, Dingiswayo helped Shaka become king of the Zulu. After Dingiswayo's death at the hands of Zwide, king of the Ndwandwe, around 1816, Shaka assumed leadership of the entire Mthethwa alliance. Shaka expanded the Zulu Kingdom through war and diplomacy. Shaka's clan at first numbered no more than a few thousands, but eventually grew in size to 45,000 after absorbing neighbouring clans. His military reforms included new battle techniques, training, and tough discipline, as well as the replacement of long throwing spears in exchange for the more effective short stabbing spears. Conscripted men were segregated from the rest of Zulu society to be trained as an organised standing army called the amabutho. The alliance under his leadership survived Zwide's first assault at the Battle of Gqokli Hill (1818). Within two years, Shaka had defeated Zwide at the Battle of Mhlatuze River (1820) and broken up the Ndwandwe alliance. The Ngoni people fled as far north as Tanzania and Malawi. By 1822, Shaka had conquered an empire covering an area of around 80,000 square miles (210,000 km2), covering Pongola to the Tugera Rivers.
== Signs and symptoms == People with CIP/CIM have diffuse, symmetric, flaccid muscle weakness. CIP/CIM typically develops in the setting of a critical illness and immobilization, so patients with CIP/CIM are often receiving treatment in the intensive care unit (ICU). Weakness (motor deficits) occurs in generalized fashion, rather than beginning in one region of the body and spreading. Limb and respiratory (diaphragm) muscles are especially affected. The muscles of the face are usually spared, but in rare cases, the eye muscles may be weakened, leading to ophthalmoplegia. Respiratory difficulties can be caused by atrophy of the muscles between the ribs (intercostals), atrophy of the diaphragm muscle, and degeneration of the nerve that stimulates the diaphragm (phrenic nerve). This can prolong the time it takes to wean a person off of a breathing machine (mechanical ventilation) by as much as 7 – 13 days. Deep tendon reflexes may be lost or diminished, and there may be bilateral symmetric flaccid paralysis of the arms and legs. The nervous system manifestations are typically limited to peripheral nerves, as the central nervous system is usually unaffected.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.